[ET Net News Agency, 10 October 2019] Sino Biopharmaceutical Limited (01177) said
Azacitidine for injection, an anticancer drug developed by Chia Tai Tianqing
Pharmaceutical Group Co., Ltd., a subsidiary of the company, has obtained approval for
drug registration granted by the National Medical Products Administration of the People's
Republic of China.
Such product is a Chemicals Category 3 drug and is the first domestic generic drug that
has completed the bioequivalence study in accordance with the draft Azacitidine Guide
issued by the United States Food and Drug Administration and passed the confirmatory
clinical trial.
Azacitidine is a cytosine nucleoside analog, being a demethylating drug with a dual
mechanism of action and currently the only clinically proven drug to improve overall
survival. (RC)